Max Weaver

Max Weaver

Auto-generated profile, based on publicly available information

Max Weaver

Sanford Imagenetics Sanford Health Sioux Falls South Dakota USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2024 in Pharmacogenomics
Verified
Journal Article
Closed access
AMAmanda Massmann
Amanda Massmann
JHJoel Van Heukelom
Joel Van Heukelom
MWMax Weaver
Max Weaver
ASApril Schultz
April Schultz
DFDebbie M Figueroa
Debbie M Figueroa
KCKurt Christensen
Kurt Christensen
Aim: Clopidogrel requires CYP2C19 activation to have antiplatelet effects. Pharmacogenetic testing to identify patients with impaired CYP2C19 function can be coupled with clinical decision support (CDS) alerts to guide antiplatelet prescribing. We evaluated the impact of alerts on clopidogrel prescribing.Materials & methods: We retrospectively analyzed data for 866 patients in which CYP2C19-clopidogrel CDS was deployed at a single healthcare system during 2015-2023.Results: Analyses included 2,288 alerts. CDS acceptance rates increased from 24% in 2015 to 63% in 2023 (p < 0.05). Adjusted analyses also showed higher acceptance rates when clopidogrel had been ordered for a percutaneous intervention (OR: 28.7, p < 0.001) and when cardiologists responded to alerts (OR: 2.11, p = 0.001).Conclusion: CDS for CYP2C19-clopidogrel was effective in reducing potential drug-gene interactions. Its influence varied by clinician specialty and medication indications.

3 May 2024 in JACCP: Journal of the American College of Clinical Pharmacy
Verified
Journal Article
Closed access
JHJoel Van Heukelom
Joel Van Heukelom
MWMax Weaver
Max Weaver
CMCarson Max
Carson Max
JBJordan Baye
Jordan Baye
APAshley Peterson
Ashley Peterson
AMAmanda Massmann
Amanda Massmann

9 December 2025 in American Journal of Health-System Pharmacy
Verified
Journal Article
Closed access
BMBrian R Meissner
Brian R Meissner
FYFatme Younes
Fatme Younes
AMAmanda Massmann
Amanda Massmann
MWMax Weaver
Max Weaver
NPNatasha J. Petry
Natasha J. Petry
Purpose: The aim of this study was to investigate the influence of CYP2D6 functionality on metabolic abnormalities in patients prescribed aripiprazole. Methods: A retrospective cohort review was conducted in patients who had CYP2D6 genotyping and an oral prescription for aripiprazole. Primary outcomes were changes in metabolic parameters from baseline based on CYP2D6 genotype–based phenotype. Patients concurrently taking medications that cause CYP2D6 inhibition were classified as phenoconverters and were categorized as poor metabolizers in subanalyses. Index and post-aripiprazole (after either initiation or dose modification) data were abstracted from the electronic medical record for the following endpoints: body mass index (BMI), blood glucose, glycated hemoglobin, low-density lipoprotein (LDL), triglycerides, and total cholesterol. Results: In multivariate mixed-effects analysis of 1,562 patients, the genotype-based phenotype cohort had no significant differences. A marginal difference in triglyceride levels was observed between poor metabolizers and normal metabolizers (β = 23.42; range, –4.9 to 51.73; P = 0.11). Findings were similar between poor metabolizers and normal metabolizers when evaluating outcomes encompassing phenoconversion, although poor metabolizers had an increased mean change in LDL levels (β = 10.04; range, 1.46 to 18.61; P < 0.05) and had a decreased mean change in BMI (β = –0.34; range, –0.72 to 0.04; P = 0.08); however, these differences were not statistically significant. Conclusion: This study suggests that the incidence of metabolic abnormalities beyond LDL may not be higher in CYP2D6 poor metabolizers compared to normal metabolizers. Further research is needed to investigate clinically meaningful outcomes in relation to CYP2D6 and aripiprazole.

1 December 2025 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
AMAmanda Massmann
Amanda Massmann
JBJordan Baye
Jordan Baye
MWMax Weaver
Max Weaver

9 August 2026 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
MWMax Weaver
Max Weaver
NPNatasha J. Petry
Natasha J. Petry
JCJeremy Cauwels
Jeremy Cauwels
RLRoxana A. Lupu
Roxana A. Lupu
AMAmanda Massmann
Amanda Massmann

9 March 2026 in Clinical and Translational Science
Verified
Journal Article
Open access
KJKristen Jacobsen
Kristen Jacobsen
NPNatasha J. Petry
Natasha J. Petry
MWMax Weaver
Max Weaver
EWEthan Weeder
Ethan Weeder
AMAmanda Massmann
Amanda Massmann
Pharmacogenomics (PGx) utilizes genetic information to optimize medication management. Barriers to PGx implementation include limited confidence and knowledge in applying results, time constraints, and financial barriers. Clinical services across health systems vary greatly with differing consultative PGx service models. Most research on clinicians and PGx has been centered around attitudes and perspectives, with limited data regarding clinician satisfaction with PGx clinical services. An internally developed survey was created to assess clinician satisfaction with PGx services across a single health system. A survey was deployed to 645 clinicians (physicians, advanced practice providers, and genetic counselors) who utilized PGx clinical services (ordered PGx testing or a referral to the PGx clinic) within the past 3 years. Surveys were distributed via secure email in June 2025. A total of 36 out of 645 clinicians participated in the survey, which is noted as a limitation. Respondents tended to be satisfied (“somewhat satisfied” or “very satisfied”) across several clinical service domains (e.g., process of ordering PGx testing, integration into the electronic health record, and return of PGx results). Pharmacist notes and clinical decision support yielded the highest satisfaction. Most clinicians reported PGx results have positively impacted patient outcomes. Nearly half of respondents noted experiencing barriers in explaining PGx results to patients. The PGx clinic may help mitigate barriers in explaining PGx results to patients. Overall, responding clinicians were satisfied with the majority of PGx clinical services.